Sickle cell disease vasculopathy: A state of nitric oxide resistance

Free Radical Biology and Medicine

Volumn 44, Issue 8, 2008, Pages 1506-1528

  Wood, Katherine C ^a   Hsu, Lewis L ^b   Gladwin, Mark T ^a,c  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Endothelium; Hemolysis; NADPH oxidase; Nitric oxide; Nitric oxide resistance; Reactive oxygen species; Vasculopathy; Xanthine oxidase

Indexed keywords

APOCYNIN; APOLIPOPROTEIN A1; ARGININE; DIPHENYLIODONIUM SALT; ENDOTHELIN 1; HEME OXYGENASE 1; HEMOGLOBIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SALAZOSULFAPYRIDINE; VITAMIN; XANTHINE OXIDASE;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BLOOD FLOW; DRUG ACTIVITY; DRUG INHIBITION; ENDOTHELIUM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYSIS; HUMAN; LEG ULCER; NONHUMAN; OXIDATION; OXIDATIVE STRESS; OXYGENATION; PRIAPISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; REVIEW; SICKLE CELL ANEMIA; STROKE; THROMBOCYTE ACTIVATION; VASCULAR DISEASE; VASOCONSTRICTION; VITAMIN SUPPLEMENTATION;

ANEMIA, SICKLE CELL; ANIMALS; ENDOTHELIUM, VASCULAR; HEMOLYSIS; HUMANS; MICE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; VASCULAR RESISTANCE;

ANIMALIA;

EID: 41549136868     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2008.01.008     Document Type: Review

References (289)

1. Frenette P.S., and Atweh G.F. Sickle cell disease: old discoveries, new concepts, and future promise. J. Clin. Invest. 117 (2007) 850-858
2. Lanzkron S., Haywood Jr. C., Segal J.B., and Dover G.J. Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea. Am. J. Hematol. 81 (2006) 927-932
3. Nietert P.J., Silverstein M.D., and Abboud M.R. Sickle cell anaemia: epidemiology and cost of illness. Pharmacoeconomics 20 (2002) 357-366
4. Mayer M.L., Konrad T.R., and Dvorak C.C. Hospital resource utilization among patients with sickle cell disease. J. Health Care Poor Underserved 14 (2003) 122-135
5. Shankar S.M., Arbogast P.G., Mitchel E., Cooper W.O., Wang W.C., and Griffin M.R. Medical care utilization and mortality in sickle cell disease: a population-based study. Am. J. Hematol. 80 (2005) 262-270
6. Davis H., Moore Jr. R.M., and Gergen P.J. Cost of hospitalizations associated with sickle cell disease in the United States. Public Health Rep. 112 (1997) 40-43
7. Platt O.S., Brambilla D.J., Rosse W.F., Milner P.F., Castro O., Steinberg M.H., and Klug P.P. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N. Engl. J. Med. 330 (1994) 1639-1644
8. Kaul D.K., and Hebbel R.P. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J. Clin. Invest. 106 (2000) 411-420
9. Powars D., Weidman J.A., Odom-Maryon T., Niland J.C., and Johnson C. Sickle cell chronic lung disease: prior morbidity and the risk of pulmonary failure. Medicine 67 (1988) 66-76
10. Hebbel R.P., Morgan W.T., Eaton J.W., and Hedlund B.E. Accelerated autoxidation and heme loss due to instability of sickle hemoglobin. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 237-241
11. Shartava A., Korn W., Shah A.K., and Goodman S.R. Irreversibly sickled cell beta-actin: defective filament formation. Am. J. Hematol. 55 (1997) 97-103
12. Aslan M., Ryan T.M., Townes T.M., Coward L., Kirk M.C., Barnes S., Alexander C.B., Rosenfeld S.S., and Freeman B.A. Nitric oxide-dependent generation of reactive species in sickle cell disease. Actin tyrosine induces defective cytoskeletal polymerization. J. Biol. Chem. 278 (2003) 4194-4204
13. Aslan M., Ryan T.M., Adler B., Townes T.M., Parks D.A., Thompson J.A., Tousson A., Gladwin M.T., Patel R.P., Tarpey M.M., Batinic-Haberle I., White C.R., and Freeman B.A. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 15215-15220
14. Ignarro L.J., Byrns R.E., Buga G.M., and Wood K.S. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical. Circ. Res. 61 (1987) 866-879
15. Vargas H.M., Cuevas J.M., Ignarro L.J., and Chaudhuri G. Comparison of the inhibitory potencies of N(G)-methyl-, N(G)-nitro-and N(G)-amino-L-arginine on EDRF function in the rat: evidence for continuous basal EDRF release. J. Pharmacol. Exp. Ther. 257 (1991) 1208-1215
16. Rees D.D., Palmer R.M., and Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc. Natl. Acad. Sci. U. S. A. 86 (1989) 3375-3378
17. Aisaka K., Gross S.S., Griffith O.W., and Levi R. NG-methylarginine, an inhibitor of endothelium-derived nitric oxide synthesis, is a potent pressor agent in the guinea pig: does nitric oxide regulate blood pressure in vivo?. Biochem. Biophys. Res. Commun. 160 (1989) 881-886
18. Rongen G.A., Smits P., and Thien T. Endothelium and the regulation of vascular tone with emphasis on the role of nitric oxide. Physiology, pathophysiology and clinical implications. Neth. J. Med. 44 (1994) 26-35
19. Kurtz A., and Wagner C. Role of nitric oxide in the control of renin secretion. Am. J. Physiol. 275 (1998) F849-F862
20. Boulanger C., and Luscher T.F. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J. Clin. Invest. 85 (1990) 587-590
21. Ghalayini I.F. Nitric oxide-cyclic GMP pathway with some emphasis on cavernosal contractility. Int. J. Impot. Res. 16 (2004) 459-469
22. Lau K.S., Grange R.W., Isotani E., Sarelius I.H., Kamm K.E., Huang P.L., and Stull J.T. nNOS and eNOS modulate cGMP formation and vascular response in contracting fast-twitch skeletal muscle. Physiol. Genomics 2 (2000) 21-27
23. Meng W., Ma J., Ayata C., Hara H., Huang P.L., Fishman M.C., and Moskowitz M.A. ACh dilates pial arterioles in endothelial and neuronal NOS knockout mice by NO-dependent mechanisms. Am. J. Physiol. 271 (1996) H1145-H1150
24. Simionescu M., and Simionescu N. Functions of the endothelial cell surface. Annu. Rev. Physiol. 48 (1986) 279-293
25. Struiker Boudier H. Pharmacological improvement of the microcirculation (2003), Springer-Verlag, Paris
26. Beckman J.S., and Crow J.P. Pathological implications of nitric oxide, superoxide and peroxynitrite formation. Biochem. Soc. Trans. 21 (1993) 330-334
27. Radi R., Denicola A., and Freeman B.A. Peroxynitrite reactions with carbon dioxide-bicarbonate. Methods Enzymol. 301 (1999) 353-367
28. Freeman B.A., and Crapo J.D. Biology of disease: free radicals and tissue injury. Lab. Invest. 47 (1982) 412-426
29. Durante W., Kroll M.H., Christodoulides N., Peyton K.J., and Schafer A.I. Nitric oxide induces heme oxygenase-1 gene expression and carbon monoxide production in vascular smooth muscle cells. Circ. Res. 80 (1997) 557-564
30. Sheftel A.D., Kim S.F., and Ponka P. Non-heme induction of heme oxygenase-1 does not alter cellular iron metabolism. J. Biol. Chem. 282 (2007) 10480-10486
31. Jiang F., Roberts S.J., Datla S., and Dusting G.J. NO modulates NADPH oxidase function via heme oxygenase-1 in human endothelial cells. Hypertension 48 (2006) 950-957
32. Baranano D.E., Rao M., Ferris C.D., and Snyder S.H. Biliverdin reductase: a major physiologic cytoprotectant. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 16093-16098
33. Nakao A., Otterbein L.E., Overhaus M., Sarady J.K., Tsung A., Kimizuka K., Nalesnik M.A., Kaizu T., Uchiyama T., Liu F., Murase N., Bauer A.J., and Bach F.H. Biliverdin protects the functional integrity of a transplanted syngeneic small bowel. Gastroenterology 127 (2004) 595-606
34. Tailor A., Cooper D., and Granger D.N. Platelet-vessel wall interactions in the microcirculation. Microcirculation 12 (2005) 275-285
35. Spiecker M., Darius H., Kaboth K., Hubner F., and Liao J.K. Differential regulation of endothelial cell adhesion molecule expression by nitric oxide donors and antioxidants. J. Leukoc. Biol. 63 (1998) 732-739
36. Schafer A., Alp N.J., Cai S., Lygate C.A., Neubauer S., Eigenthaler M., Bauersachs J., and Channon K.M. Reduced vascular NO bioavailability in diabetes increases platelet activation in vivo. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 1720-1726
37. Schafer A., Widder J., Eigenthaler M., Ertl G., and Bauersachs J. Reduced basal nitric oxide bioavailability and platelet activation in young spontaneously hypertensive rats. Biochem. Pharmacol. 67 (2004) 2273-2279
38. Dambisya Y.M., and Lee T.L. A thromboelastography study on the in vitro effects of L-arginine and L-NG-nitro arginine methyl ester on human whole blood coagulation and fibrinolysis. Blood Coagul. Fibrinolysis 7 (1996) 678-683
39. Dusse L.M., Cooper A.J., and Lwaleed B.A. Tissue factor and nitric oxide: a controversial relationship!. J. Thromb. Thrombolysis 23 (2007) 129-133
40. Schini-Kerth V.B. Vascular biosynthesis of nitric oxide: effect on hemostasis and fibrinolysis. Transfus. Clin. Biol. 6 (1999) 355-363
41. Raghavachari N., Xu X., Harris A., Villagra J., Logun C., Barb J., Solomon M.A., Suffredini A.F., Danner R.L., Kato G., Munson P.J., Morris Jr. S.M., and Gladwin M.T. Amplified expression profiling of platelet transcriptome reveals changes in arginine metabolic pathways in patients with sickle cell disease. Circulation 115 (2007) 1551-1562
42. Quyyumi A.A., Dakak N., Andrews N.P., Husain S., Arora S., Gilligan D.M., Panza J.A., and Cannon III R.O. Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis. J. Clin. Invest. 95 (1995) 1747-1755
43. Reiter C.D., Wang X., Tanus-Santos J.E., Hogg N., Cannon III R.O., Schechter A.N., and Gladwin M.T. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat. Med. 8 (2002) 1383-1389
44. Gladwin M.T., Schechter A.N., Ognibene F.P., Coles W.A., Reiter C.D., Schenke W.H., Csako G., Waclawiw M.A., Panza J.A., and Cannon III R.O. Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation 107 (2003) 271-278
45. Eberhardt R.T., McMahon L., Duffy S.J., Steinberg M.H., Perrine S.P., Loscalzo J., Coffman J.D., and Vita J.A. Sickle cell anemia is associated with reduced nitric oxide bioactivity in peripheral conduit and resistance vessels. Am. J. Hematol. (2003) 104-111
46. Nath K.A., Shah V., Haggard J.J., Croatt A.J., Smith L.A., Hebbel R.P., and Katusic Z.S. Mechanisms of vascular instability in a transgenic mouse model of sickle cell disease. Am. J. Physiol., Regul. Integr. Comp. Physiol. 279 (2000) R1949-R1955
47. Kaul D.K., Liu X.D., Fabry M.E., and Nagel R.L. Impaired nitric oxide-mediated vasodilation in transgenic sickle mouse. Am. J. Physiol., Circ. Physiol. 278 (2000) H1799-H1806
48. Kaul D.K., Liu X.D., Chang H.Y., Nagel R.L., and Fabry M.E. Effect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice. J. Clin. Invest. 114 (2004) 1136-1145
49. Pritchard Jr. K.A., Ou J., Ou Z., Shi Y., Franciosi J.P., Signorino P., Kaul S., Ackland-Berglund C., Witte K., Holzhauer S., Mohandas N., Guice K.S., Oldham K.T., and Hillery C.A. Hypoxia-induced acute lung injury in murine models of sickle cell disease. Am. J. Physiol., Lung Cell Mol. Physiol. 286 (2004) L705-L714
50. Wood K.C., Hebbel R.P., and Granger D.N. Endothelial cell NADPH oxidase mediates the cerebral microvascular dysfunction in sickle cell transgenic mice. FASEB J. 19 (2005) 989-991
51. Hsu L.L., Champion H.C., Campbell-Lee S.A., Bivalacqua T.J., Manci E.A., Diwan B.A., Schimel D.M., Cochard A.E., Wang X., Schechter A.N., Noguchi C.T., and Gladwin M.T. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood 109 (2007) 3088-3098
52. Jeffers A., Gladwin M.T., and Kim-Shapiro D.B. Computation of plasma hemoglobin nitric oxide scavenging in hemolytic anemias. Free Radic. Biol. Med. 41 (2006) 1557-1565
53. Fink B., Laude K., McCann L., Doughan A., Harrison D.G., and Dikalov S. Detection of intracellular superoxide formation in endothelial cells and intact tissues using dihydroethidium and an HPLC-based assay. Am. J. Physiol., Cell Physiol. 287 (2004) C895-C902
54. Zhao H., Kalivendi S., Zhang H., Joseph J., Nithipatikom K., Vasquez-Vivar J., and Kalyanaraman B. Superoxide reacts with hydroethidine but forms a fluorescent product that is distinctly different from ethidium: potential implications in intracellular fluorescence detection of superoxide. Free Radic. Biol. Med. 34 (2003) 1359-1368
55. Buxton G.V., Greenstock C.L., Helman W.P., and Ross A.B. Critical review of rate constants for reactions of hydrated electrons, hydrogen atoms and hydroxyl radicals (.OH/.O-) in aqueous solution. J. Phys. Chem. Ref. Data 17 (1988) 513-886
56. Castro L., Rodriguez M., and Radi R. Aconitase is readily inactivated by peroxynitrite, but not by its precursor, nitric oxide. J. Biol. Chem. 269 (1994) 29409-29415
57. Janiszewski M., Souza H.P., Liu X., Pedro M.A., Zweier J.L., and Laurindo F.R. Overestimation of NADH-driven vascular oxidase activity due to lucigenin artifacts. Free Radic. Biol. Med. 32 (2002) 446-453
58. Stasch J.P., Schmidt P.M., Nedvetsky P.I., Nedvetskaya T.Y., H. S. A., Meurer S., Deile M., Taye A., Knorr A., Lapp H., Muller H., Turgay Y., Rothkegel C., Tersteegen A., Kemp-Harper B., Muller-Esterl W., and Schmidt H.H. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J. Clin. Invest. 116 (2006) 2552-2561
59. Conran N., Oresco-Santos C., Acosta H.C., Fattori A., Saad S.T., and Costa F.F. Increased soluble guanylate cyclase activity in the red blood cells of sickle cell patients. Br. J. Haematol. 124 (2004) 547-554
60. Pegelow C.H., Colangelo L., Steinberg M., Wright E.C., Smith J., Phillips G., and Vichinsky E. Natural history of blood pressure in sickle cell disease: risks for stroke and death associated with relative hypertension in sickle cell anemia. Am. J. Med. 102 (1997) 171-177
61. Klings E.S., Christman B.W., McClung J., Stucchi A.F., McMahon L., Brauer M., and Farber H.W. Increased F2 isoprostanes in the acute chest syndrome of sickle cell disease as a marker of oxidative stress. Am. J. Respir. Crit. Care Med. 164 (2001) 1248-1252
62. Munzel T., Daiber A., and Mulsch A. Explaining the phenomenon of nitrate tolerance. Circ. Res. 97 (2005) 618-628
63. Wenzel P., Oelze M., Coldewey M., Hortmann M., Seeling A., Hink U., Mollnau H., Stalleicken D., Weiner H., Lehmann J., Li H., Forstermann U., Munzel T., and Daiber A. Heme oxygenase-1: a novel key player in the development of tolerance in response to organic nitrates. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 1729-1735
64. McCurdy P.R., and Sherman A.S. Irreversibly sickled cells and red cell survival in sickle cell anemia. A study wtih both DF32P and 51Cr. Am. J. Med. 64 (1978) 253
65. Serjeant G.R., Serjeant B.E., and Milner P.F. The irreversibly sickled cell: A determinant of hemolysis in sickle cell anemia. Br. J. Haematol. 17 (1969) 527
66. Franco R.S., Lohmann J., Silberstein E.B., Mayfield-Pratt G., Palascak M., Nemeth T.A., Joiner C.H., Weiner M., and Rucknagel D.L. Time-dependent changes in the density and hemoglobin F content of biotin-labeled sickle cells. J. Clin. Invest. 101 (1998) 2730-2740
67. Chen Y.H., and Wang S.C. A simple model for estimating the hemolytic rate in patients with sickle cell anemia. J. Lab. Clin. Med. 105 (1985) 201-208
68. Brugnara C., Zelmanovic D., Sorette M., Ballas S.K., and Platt O. Reticulocyte hemoglobin: an integrated parameter for evaluation of erythropoietic activity. Am. J. Clin. Pathol. 108 (1997) 133-142
69. Kato G.J., McGowan V., Machado R.F., Little J.A., Taylor J.t., Morris C.R., Nichols J.S., Wang X., Poljakovic M., Morris Jr. S.M., and Gladwin M.T. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 107 (2006) 2279-2285
70. Karayalcin G., Lanzkowsky P., and Kari A.B. Serum alpha-hydroxybutyrate dehydrogenase levels in children with sickle cell disease. Am. J. Pediatr. Hematol. Oncol. 3 (1981) 169-171
71. Maddrey W.C., Cukier J.O., Maglalang A.C., Boitnott J.K., and Odell G.B. Hepatic bilirubin UDP-glucuronyltransferase in patients with sickle cell anemia. Gastroenterology 74 (1978) 193-195
72. Passon R.G., Howard T.A., Zimmerman S.A., Schultz W.H., and Ware R.E. Influence of bilirubin uridine diphosphate-glucuronosyltransferase 1A promoter polymorphisms on serum bilirubin levels and cholelithiasis in children with sickle cell anemia. J. Pediatr. Hematol. Oncol. 23 (2001) 448-451
73. Serjeant G., Serjeant B., Stephens A., Roper D., Higgs D., Beckford M., Cook J., and Thomas P. Determinants of haemoglobin level in steady-state homozygous sickle cell disease. Br. J. Haematol. 92 (1996) 143-149
74. Brown A.K., Sleeper L.A., Miller S.T., Pegelow C.H., Gill F.M., and Waclawiw M.A. Reference values and hematologic changes from birth to 5 years in patients with sickle cell disease. Cooperative Study of Sickle Cell Disease. Arch. Pediatr. Adolesc. Med. 148 (1994) 796-804
75. Solanki D.L., McCurdy P.R., Cuttitta F.F., and Schechter G.P. Hemolysis in sickle cell disease as measured by endogenous carbon monoxide production. A preliminary report. Am. J. Clin. Pathol. 89 (1988) 221-225
76. White J.M., Billimoria F., Muller M.A., Davis L.R., and Stroud C.E. Serum-alpha-hydroxybutyrate dehydrogenase levels in sickle-cell disease and sickle-cell crisis. Lancet 1 (1978) 532-533
77. Ballas S.K., and Marcolina M.J. Hyperhemolysis during the evolution of uncomplicated acute painful episodes in patients with sickle cell anemia. Transfusion 46 (2006) 105-110
78. Stuart M.J., and Nagel R.L. Sickle-cell disease. Lancet 364 (2004) 1343-1360
79. Ballas S.K., Marcolina M.J., Dover G.J., and Barton F.B. Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. Br. J. Haematol. 105 (1999) 491-496
80. Franco R.S., Yasin Z., Palascak M.B., Ciraolo P., Joiner C.H., and Rucknagel D.L. The effect of fetal hemoglobin on the survival characteristics of sickle cells. Blood 108 (2006) 1073-1076
81. Ataga K.I., Smith W.R., DeCastro L.M., Swerdlow P., Saunthararajah Y., Castro O., Vichinsky E., Kutlar A., Orringer E.P., Rigdon G.C., and Stocker J.W. Efficacy and safety of the Gardos channel blocker, Senicapoc (ICA-17043), in patients with sickle cell anemia. Blood First Edition Online (2008) Jan 11
82. Solanki D. Erythrophagocytosis in vivo in sickle cell anemia. Am. J. Hematol. 20 (1985) 353-357
83. Hebbel R.P., and Miller W.J. Phagocytosis of sickle erythrocytes: immunologic and oxidative determinants of hemolytic anemia. Blood 64 (1984) 733-741
84. Brugnara C. Therapeutic strategies for prevention of sickle cell dehydration. Blood Cells Mol. Dis. 27 (2001) 71-80
85. Aldrich T.K., Dhuper S.K., Patwa N.S., Makolo E., Suzuka S.M., Najeebi S.A., Santhanakrishnan S., Nagel R.L., and Fabry M.E. Pulmonary entrapment of sickle cells: the role of regional alveolar hypoxia. J. Appl. Physiol. 80 (1996) 531-539
86. Pearson H.A., Gallagher D., Chilcote R., Sullivan E., Wilimas J., Espeland M., and Ritchey A.K. Developmental pattern of splenic dysfunction in sickle cell disorders. Pediatrics 76 (1985) 392-397
87. Lee E.S., and Chu P.C. Reverse sequestration in a case of sickle crisis. Postgrad. Med. J. 72 (1996) 487-488
88. Pearson H.A., Spencer R.P., and Cornelius E.A. Functional asplenia in sickle-cell anemia. N. Engl. J. Med. 281 (1969) 923-926
89. Lane P.A., O'Connell J.L., Lear J.L., Rogers Z.R., Woods G.M., Hassell K.L., Wethers D.L., Luckey D.W., and Buchanan G.R. Functional asplenia in hemoglobin SC disease. Blood 85 (1995) 2238-2244
90. Test S.T., and Woolworth V.S. Defective regulation of complement by the sickle erythrocyte: evidence for a defect in control of membrane attack complex formation. Blood 83 (1994) 842-852
91. MacCallum R.N., Lynch E.C., Hellums J.D., and Alfrey Jr. C.P. Fragility of abnormal erythrocytes evaluated by response to shear stress. J. Lab. Clin. Med. 85 (1975) 67-74
92. Hebbel R.P., Eaton J.W., Balasingam M., and Steinberg M.H. Spontaneous oxygen radical generation by sickle erythrocytes. J. Clin. Invest. 70 (1982) 1253-1259
93. Rank B.H., Carlsson J., and Hebbel R.P. Abnormal redox status of membrane-protein thiols in sickle erythrocytes. J. Clin. Invest. 75 (1985) 1531-1537
94. Das S.K., and Nair R.C. Superoxide dismutase, glutathione peroxidase, catalase and lipid peroxidation of normal and sickled erythrocytes. Br. J. Haematol. 44 (1980) 87-92
95. Iyamu E.W., Cecil R., Parkin L., Woods G., Ohene-Frempong K., and Asakura T. Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy. Br. J. Haematol. 131 (2005) 389-394
96. Chiu D., Vichinsky E., Yee M., Kleman K., and Lubin B. Peroxidation, vitamin E, and sickle-cell anemia. Ann. N. Y. Acad. Sci. 393 (1982) 323-335
97. Kuypers F.A., Scott M.D., Schott M.A., Lubin B., and Chiu D.T. Use of ektacytometry to determine red cell susceptibility to oxidative stress. J. Lab. Clin. Med. 116 (1990) 535-545
98. Claster S., Chiu D.T., Quintanilha A., and Lubin B. Neutrophils mediate lipid peroxidation in human red cells. Blood 64 (1984) 1079-1084
99. Claster S., Quintanilha A., Schott M.A., Chiu D., and Lubin B. Neutrophil-induced K + leak in human red cells: a potential mechanism for infection-mediated hemolysis. J. Lab. Clin. Med. 109 (1987) 201-210
100. Hebbel R.P., Leung A., and Mohandas N. Oxidation-induced changes in microrheologic properties of the red blood cell membrane. Blood 76 (1990) 1015-1020
101. Makhijani V.B., and Cokelet G.R. In vivo polymerization of sickle-cell hemoglobin: a theoretical study. Blood Cells 20 (1994) 169-183
102. Makhijani V.B., Cokelet G.R., and Clark Jr. A. Dynamics of oxygen unloading from sickle erythrocytes. Biophys. J. 58 (1990) 1025-1052
103. Ferrone F.A. The polymerization of sickle hemoglobin in solutions and cells. Experientia 49 (1993) 110-117
104. Ferrone F.A., and Rotter M.A. Crowding and the polymerization of sickle hemoglobin. J. Mol. Recognit. 17 (2004) 497-504
105. Nash G.B., Johnson C.S., and Meiselman H.J. Influence of oxygen tension on the viscoelastic behavior of red blood cells in sickle cell disease. Blood 67 (1986) 110-118
106. Brown M.D., Wick T.M., and Eckman J.R. Activation of vascular endothelial cell adhesion molecule expression by sickle blood cells. Pediatr. Pathol. Mol. Med. 20 (2001) 47-72
107. Montes R.A., Eckman J.R., Hsu L.L., and Wick T.M. Sickle erythrocyte adherence to endothelium at low shear: role of shear stress in propagation of vaso-occlusion. Am. J. Hematol. 70 (2002) 216-227
108. Wagner M.C., Eckman J.R., and Wick T.M. Sickle cell adhesion depends on hemodynamics and endothelial activation. J. Lab. Clin. Med. 144 (2004) 260-267 discussion: 227-268
109. Liu X., Miller M.J., Joshi M.S., Sadowska-Krowicka H., Clark D.A., and Lancaster Jr. J.R. Diffusion-limited reaction of free nitric oxide with erythrocytes. J. Biol. Chem. 273 (1998) 18709-18713
110. Liao J.C., Hein T.W., Vaughn M.W., Huang K.T., and Kuo L. Intravascular flow decreases erythrocyte consumption of nitric oxide. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 8757-8761
111. Coin J.T., and Olson J.S. The rate of oxygen uptake by human red blood cells. J. Biol. Chem. 254 (1979) 1178-1190
112. Space S.L., Lane P.A., Pickett C.K., and Weil J.V. Nitric oxide attenuates normal and sickle red blood cell adherence to pulmonary endothelium. Am. J. Hematol. 63 (2000) 200-204
113. Kasuya H., Weir B.K., White D.M., and Stefansson K. Mechanism of oxyhemoglobin-induced release of endothelin-1 from cultured vascular endothelial cells and smooth-muscle cells. J. Neurosurg. 79 (1993) 892-898
114. Villagra J., Shiva S., Hunter L.A., Machado R.F., Gladwin M.T., and Kato G.J. Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension and nitric oxide scavenging by cell-free hemoglobin. Blood 110 (2007) 2166-2172
115. Mondoro T.H., Ryan B.B., Hrinczenko B.W., Schechter A.N., Vostal J.G., and Alayash A.I. Biological action of nitric oxide donor compounds on platelets from patients with sickle cell disease. Br. J. Haematol. 112 (2001) 1048-1054
116. Olmos L., Mombouli J.V., Wasserstrum N., and Vanhoutte P.M. Ability of sickle cells to scavenge endothelium-derived nitric oxide is reduced. Acta Pharmacol. Sin. 23 (2002) 967-973
117. Rother R.P., Bell L., Hillmen P., and Gladwin M.T. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA 293 (2005) 1653-1662
118. Morris C.R., Kato G.J., Poljakovic M., Wang X., Blackwelder W.C., Sachdev V., Hazen S.L., Vichinsky E.P., Morris Jr. S.M., and Gladwin M.T. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA 294 (2005) 81-90
119. Morris C.R., Morris Jr. S.M., Hagar W., Van Warmerdam J., Claster S., Kepka-Lenhart D., Machado L., Kuypers F.A., and Vichinsky E.P. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease?. Am. J. Respir. Crit. Care Med. 168 (2003) 63-69
120. Ascenzi P., Bocedi A., Visca P., Altruda F., Tolosano E., Beringhelli T., and Fasano M. Hemoglobin and heme scavenging. IUBMB Life 57 (2005) 749-759
121. Anderson G.J., and Frazer D.M. Hepatic iron metabolism. Semin. Liver Dis. 25 (2005) 420-432
122. Van Vlierberghe H., Langlois M., and Delanghe J. Haptoglobin polymorphisms and iron homeostasis in health and in disease. Clin. Chim. Acta 345 (2004) 35-42
123. Noyes W.D., and Garby L. Rate of haptoglobin in synthesis in normal man. Determinations by the return to normal levels following hemoglobin infusion. Scand. J. Clin. Lab. Invest. 20 (1967) 33-38
124. Muller-Eberhard U., Javid J., Liem H.H., Hanstein A., and Hanna M. Plasma concentrations of hemopexin, haptoglobin and heme in patients with various hemolytic diseases. Blood 32 (1968) 811-815
125. Nielsen M.J., Petersen S.V., Jacobsen C., Oxvig C., Rees D., Moller H.J., and Moestrup S.K. Haptoglobin-related protein is a high-affinity hemoglobin-binding plasma protein. Blood 108 (2006) 2846-2849
126. Ou J., Ou Z., Jones D.W., Holzhauer S., Hatoum O.A., Ackerman A.W., Weihrauch D.W., Gutterman D.D., Guice K., Oldham K.T., Hillery C.A., and Pritchard Jr. K.A. L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation 107 (2003) 2337-2341
127. Hvidberg V., Maniecki M.B., Jacobsen C., Hojrup P., Moller H.J., and Moestrup S.K. Identification of the receptor scavenging hemopexin-heme complexes. Blood 106 (2005) 2572-2579
128. Liu Y., Liu J., Tetzlaff W., Paty D.W., and Cynader M.S. Biliverdin reductase, a major physiologic cytoprotectant, suppresses experimental autoimmune encephalomyelitis. Free Radic. Biol. Med. 40 (2006) 960-967
129. Sedlak T.W., and Snyder S.H. Bilirubin benefits: cellular protection by a biliverdin reductase antioxidant cycle. Pediatrics 113 (2004) 1776-1782
130. Yamazaki H., Ohta K., Tsukiji H., Toma T., Hashida Y., Ishizaki A., Saito T., Arai S., Koizumi S., and Yachie A. Corticosteroid enhances heme oxygenase-1 production by circulating monocytes by up-regulating hemoglobin scavenger receptor and amplifying the receptor-mediated uptake of hemoglobin-haptoglobin complex. Biochem. Biophys. Res. Commun. 358 (2007) 506-512
131. Jison M.L., Munson P.J., Barb J.J., Suffredini A.F., Talwar S., Logun C., Raghavachari N., Beigel J.H., Shelhamer J.H., Danner R.L., and Gladwin M.T. Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease. Blood 104 (2004) 270-280
132. Belcher J.D., Mahaseth H., Welch T.E., Otterbein L.E., Hebbel R.P., and Vercellotti G.M. Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice. J. Clin. Invest. 116 (2006) 808-816
133. Bell M.J., Stockwell D.C., Luban N.L., Shirey R.S., Shaak L., Ness P.M., and Wong E.C. Ceftriaxone-induced hemolytic anemia and hepatitis in an adolescent with hemoglobin SC disease. Pediatr. Crit. Care Med. 6 (2005) 363-366
134. Talano J.A., Hillery C.A., Gottschall J.L., Baylerian D.M., and Scott J.P. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease. Pediatrics 111 (2003) e661-e665
135. Bernini J.C., Mustafa M.M., Sutor L.J., and Buchanan G.R. Fatal hemolysis induced by ceftriaxone in a child with sickle cell anemia. J. Pediatr. 126 (1995) 813-815
136. Asleh R., and Levy A.P. In vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular disease. Vasc. Health Risk Manag. 1 (2005) 19-28
137. Atkinson S.H., Rockett K., Sirugo G., Bejon P.A., Fulford A., O'Connell M.A., Bailey R., Kwiatkowski D.P., and Prentice A.M. Seasonal childhood anaemia in West Africa is associated with the haptoglobin 2-2 genotype. PLoS Med. 3 (2006) e172
138. Afolabi P.R., Jahoor F., Gibson N.R., and Jackson A.A. Response of hepatic proteins to the lowering of habitual dietary protein to the recommended safe level of intake. Am. J. Physiol. Endocrinol. Metab. 287 (2004) E327-E330
139. Suttner S.W., Surder C., Lang K., Piper S.N., Kumle B., and Boldt J. Does age affect liver function and the hepatic acute phase response after major abdominal surgery?. Intensive Care Med. 27 (2001) 1762-1769
140. Asleh R., Guetta J., Kalet-Litman S., Miller-Lotan R., and Levy A.P. Haptoglobin genotype-and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo. Circ. Res. 96 (2005) 435-441
141. Nolan V.G., Adewoye A., Baldwin C., Wang L., Ma Q., Wyszynski D.F., Farrell J.J., Sebastiani P., Farrer L.A., and Steinberg M.H. Sickle cell leg ulcers: associations with haemolysis and SNPs in Klotho, TEK and genes of the TGF-beta/BMP pathway. Br. J. Haematol. 133 (2006) 570-578
142. Lezcano N.E., Odo N., Kutlar A., Brambilla D., and Adams R.J. Regular transfusion lowers plasma free hemoglobin in children with sickle-cell disease at risk for stroke. Stroke 37 (2006) 1424-1426
143. Adams R.J., Kutlar A., McKie V., Carl E., Nichols F.T., Liu J.C., McKie K., and Clary A. Alpha thalassemia and stroke risk in sickle cell anemia. Am. J. Hematol. 45 (1994) 279-282
144. Nolan V.G., Wyszynski D.F., Farrer L.A., and Steinberg M.H. Hemolysis-associated priapism in sickle cell disease. Blood 106 (2005) 3264-3267
145. Christakis J., Vavatsi N., Hassapopoulou H., Papadopoulou M., Mandraveli K., Loukopoulos D., Morris J.S., Serjeant B.E., and Serjeant G.R. Comparison of homozygous sickle cell disease in northern Greece and Jamaica. Lancet 335 (1990) 637-640
146. Nelson S.C., Adade B.B., McDonough E.A., Moquist K.L., and Hennessy J.M. High prevalence of pulmonary hypertension in children with sickle cell disease. J. Pediatr. Hematol. Oncol. 29 (2007) 334-337
147. Ataga K.I., Moore C.G., Jones S., Olajide O., Strayhorn D., Hinderliter A., and Orringer E.P. Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. Br. J. Haematol. 134 (2006) 109-115
148. Ambrusko S.J., Gunawardena S., Sakara A., Windsor B., Lanford L., Michelson P., and Krishnamurti L. Elevation of tricuspid regurgitant jet velocity, a marker for pulmonary hypertension in children with sickle cell disease. Pediatr. Blood Cancer 47 (2006) 907-913
149. Castro O., and Gladwin M.T. Pulmonary hypertension in sickle cell disease: mechanisms, diagnosis, and management. Hematol. Oncol. Clin. North Am. 19 (2005) 881-896 vii
150. Voskaridou E., Tsetsos G., Tsoutsias A., Spyropoulou E., Christoulas D., and Terpos E. Pulmonary hypertension in patients with sickle cell/beta thalassemia: incidence and correlation with serum N-terminal pro-brain natriuretic peptide concentrations. Haematologica 92 (2007) 738-743
151. Akgul F., Yalcin F., Seyfeli E., Ucar E., Karazincir S., Balci A., and Gali E. Pulmonary hypertension in sickle-cell disease: comorbidities and echocardiographic findings. Acta Haematol. 118 (2007) 53-60
152. Gladwin M.T., Sachdev V., Jison M.L., Shizukuda Y., Plehn J.F., Minter K., Brown B., Coles W.A., Nichols J.S., Ernst I., Hunter L.A., Blackwelder W.C., Schechter A.N., Rodgers G.P., Castro O., and Ognibene F.P. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N. Engl. J. Med. 350 (2004) 886-895
153. Gladwin M.T., and Kato G.J. Cardiopulmonary complications of sickle cell disease: role of nitric oxide and hemolytic anemia. Hematol. Am. Soc. Hematol. Educ. Program 51-57 (2005)
154. Kaul D.K., Liu X.D., Choong S., Belcher J.D., Vercellotti G.M., and Hebbel R.P. Anti-inflammatory therapy ameliorates leukocyte adhesion and microvascular flow abnormalities in transgenic sickle mice. Am. J. Physiol., Heart Circ. Physiol. 287 (2004) H293-H301
155. McCord J.M. Oxygen-derived free radicals in postischemic tissue injury. N. Engl. J. Med. 312 (1985) 159-163
156. Parks D.A., Williams T.K., and Beckman J.S. Conversion of xanthine dehydrogenase to oxidase in ischemic rat intestine: a reevaluation. Am. J. Physiol. 254 (1988) G768-G774
157. Houston M., Estevez A., Chumley P., Aslan M., Marklund S., Parks D.A., and Freeman B.A. Binding of xanthine oxidase to vascular endothelium. Kinetic characterization and oxidative impairment of nitric oxide-dependent signaling. J. Biol. Chem. 274 (1999) 4985-4994
158. Jarasch E.D., Bruder G., and Heid H.W. Significance of xanthine oxidase in capillary endothelial cells. Acta Physiol. Scand., Suppl. 548 (1986) 39-46
159. Benkerrou M., Delarche C., Brahimi L., Fay M., Vilmer E., Elion J., Gougerot-Pocidalo M.A., and Elbim C. Hydroxyurea corrects the dysregulated L-selectin expression and increased H(2)O(2) production of polymorphonuclear neutrophils from patients with sickle cell anemia. Blood 99 (2002) 2297-2303
160. Agil A., and Sadrzadeh S.M. Hydroxy-urea protects erythrocytes against oxidative damage. Redox Rep. 5 (2000) 29-34
161. Griendling K.K., Sorescu D., and Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ. Res. 86 (2000) 494-501
162. Haynes Jr. J., and Obiako B. Activated polymorphonuclear cells increase sickle red blood cell retention in lung: role of phospholipids. Am. J. Physiol., Heart Circ. Physiol. 282 (2002) H122-H130
163. Wood K.C., Hebbel R.P., Lefer D.J., and Granger D.N. Critical role of endothelial cell-derived nitric oxide synthase in sickle cell disease-induced microvascular dysfunction. Free Radic. Biol. Med. 40 (2006) 1443-1453
164. Moncada S., and Higgs E.A. Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J. 9 (1995) 1319-1330
165. Alderton W.K., Cooper C.E., and Knowles R.G. Nitric oxide synthases: structure, function and inhibition. Biochem. J. 357 (2001) 593-615
166. Fasipe F.R., Ubawike A.E., Eva R., and Fabry M.E. Arginine supplementation improves rotorod performance in sickle transgenic mice. Hematology 9 (2004) 301-305
167. Romero J.R., Suzuka S.M., Nagel R.L., and Fabry M.E. Arginine supplementation of sickle transgenic mice reduces red cell density and Gardos channel activity. Blood 99 (2002) 1103-1108
168. Schnog J.J., Jager E.H., van der Dijs F.P., Duits A.J., Moshage H., Muskiet F.D., and Muskiet F.A. Evidence for a metabolic shift of arginine metabolism in sickle cell disease. Ann. Hematol. 83 (2004) 371-375
169. Stuhlinger M. [Asymmetric dimethyl arginine (ADMA): a novel cardiovascular risk factor?]. Wien Med. Wochenschr. 157 (2007) 57-60
170. Meininger C.J., Cai S., Parker J.L., Channon K.M., Kelly K.A., Becker E.J., Wood M.K., Wade L.A., and Wu G. GTP cyclohydrolase I gene transfer reverses tetrahydrobiopterin deficiency and increases nitric oxide synthesis in endothelial cells and isolated vessels from diabetic rats. FASEB J. 18 (2004) 1900-1902
171. Alp N.J., Mussa S., Khoo J., Cai S., Guzik T., Jefferson A., Goh N., Rockett K.A., and Channon K.M. Tetrahydrobiopterin-dependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted transgenic GTP-cyclohydrolase I overexpression. J. Clin. Invest. 112 (2003) 725-735
172. Zheng J.S., Yang X.Q., Lookingland K.J., Fink G.D., Hesslinger C., Kapatos G., Kovesdi I., and Chen A.F. Gene transfer of human guanosine 5′-triphosphate cyclohydrolase I restores vascular tetrahydrobiopterin level and endothelial function in low renin hypertension. Circulation 108 (2003) 1238-1245
173. Hong H.J., Hsiao G., Cheng T.H., and Yen M.H. Supplemention with tetrahydrobiopterin suppresses the development of hypertension in spontaneously hypertensive rats. Hypertension 38 (2001) 1044-1048
174. Tiefenbacher C.P., Bleeke T., Vahl C., Amann K., Vogt A., and Kubler W. Endothelial dysfunction of coronary resistance arteries is improved by tetrahydrobiopterin in atherosclerosis. Circulation 102 (2000) 2172-2179
175. Alp N.J., McAteer M.A., Khoo J., Choudhury R.P., and Channon K.M. Increased endothelial tetrahydrobiopterin synthesis by targeted transgenic GTP-cyclohydrolase I overexpression reduces endothelial dysfunction and atherosclerosis in ApoE-knockout mice. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 445-450
176. Hasanato R.M. Zinc and antioxidant vitamin deficiency in patients with severe sickle cell anemia. Ann. Saudi Med. 26 (2006) 17-21
177. Prasad A.S. Zinc deficiency in patients with sickle cell disease. Am. J. Clin. Nutr. 75 (2002) 181-182
178. Ren H., Ghebremeskel K., Lee A., Okpala I., Ibegulam O., Ugochukwu C., and Crawford M. Compromised antioxidants status may partly explain the low levels of eicosapentaenoic and docosahexaaenoic acids in patients with sickle cell disease [abstract]. 97th AOCS Annual Meeting and Expo (2006) St Louis, MO
179. Schacter L., Warth J.A., Gordon E.M., Prasad A., and Klein B.L. Altered amount and activity of superoxide dismutase in sickle cell anemia. FASEB J. 2 (1988) 237-243
180. Titus J., Suresh C., Gupta M., and Parekh N. Pro-oxidant and anti-oxidant status in patients of sickle cell anaemia. Indian J. Clin. Biochem. 19 (2004) 168-172
181. Beretta L., Gerli G.C., Ferraresi R., Agostoni A., Gualandri V., and Orsini G.B. Antioxidant system in sickle red cells. Acta Haematol. 70 (1983) 194-197
182. Varma R.N., Mankad V.N., Phelps D.D., Jenkins L.D., and Suskind R.M. Depressed erythrocyte glutathione reductase activity in sickle cell disease. Am. J. Clin. Nutr. 38 (1983) 884-887
183. Kaul D.K., Liu X.D., Zhang X., Ma L., Hsia C.J., and Nagel R.L. Inhibition of sickle red cell adhesion and vasoocclusion in the microcirculation by antioxidants. Am. J. Physiol., Heart Circ. Physiol. 291 (2006) H167-H175
184. Reid M., Badaloo A., Forrester T., and Jahoor F. In vivo rates of erythrocyte glutathione synthesis in adults with sickle cell disease. Am. J. Physiol., Endocrinol. Metab. 291 (2006) E73-E79
185. Lachant N.A., Davidson W.D., and Tanaka K.R. Impaired pentose phosphate shunt function in sickle cell disease: a potential mechanism for increased Heinz body formation and membrane lipid peroxidation. Am. J. Hematol. 15 (1983) 1-13
186. Charache S., Terrin M.L., Moore R.D., Dover G.J., Barton F.B., Eckert S.V., McMahon R.P., and Bonds D.R. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N. Engl. J. Med. 332 (1995) 1317-1322
187. Lima C.S., Arruda V.R., Costa F.F., and Saad S.T. Minimal doses of hydroxyurea for sickle cell disease. Braz. J. Med. Biol. Res. 30 (1997) 933-940
188. Gladwin M.T., and Rodgers G.P. Pathogenesis and treatment of acute chest syndrome of sickle-cell anaemia. Lancet 355 (2000) 1476-1478
189. Ferguson R.P., Arun A., Carter C., Walker S.D., and Castro O. Hydroxyurea treatment of sickle cell anemia in hospital-based practices. Am. J. Hematol. 70 (2002) 326-328
190. Steinberg M.H., Barton F., Castro O., Pegelow C.H., Ballas S.K., Kutlar A., Orringer E., Bellevue R., Olivieri N., Eckman J., Varma M., Ramirez G., Adler B., Smith W., Carlos T., Ataga K., DeCastro L., Bigelow C., Saunthararajah Y., Telfer M., Vichinsky E., Claster S., Shurin S., Bridges K., Waclawiw M., Bonds D., and Terrin M. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 289 (2003) 1645-1651
191. Kinney T.R., Helms R.W., O'Branski E.E., Ohene-Frempong K., Wang W., Daeschner C., Vichinsky E., Redding-Lallinger R., Gee B., Platt O.S., and Ware R.E. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood 94 (1999) 1550-1554
192. Moore R.D., Charache S., Terrin M.L., Barton F.B., and Ballas S.K. Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Am. J. Hematol. 64 (2000) 26-31
193. Zumberg M.S., Reddy S., Boyette R.L., Schwartz R.J., Konrad T.R., and Lottenberg R. Hydroxyurea therapy for sickle cell disease in community-based practices: a survey of Florida and North Carolina hematologists/oncologists. Am. J. Hematol. 79 (2005) 107-113
194. National Toxicology Program-Center for the Evaluation of Risks to Human Reproduction U. S. D. o. H. a. H. S. White Paper on Hydroxyurea Risk:Benefit Oct 2007. In: NTP-CERHR expert panel report on the reproductive and developmental toxicity of hydroxyurea, 2007.
195. Saleh A.W., Hillen H.F., and Duits A.J. Levels of endothelial, neutrophil and platelet-specific factors in sickle cell anemia patients during hydroxyurea therapy. Acta Haematol. 102 (1999) 31-37
196. Conran N., Fattori A., Saad S.T., and Costa F.F. Increased levels of soluble ICAM-1 in the plasma of sickle cell patients are reversed by hydroxyurea. Am. J. Hematol. 76 (2004) 343-347
197. Cokic V.P., Beleslin-Cokic B.B., Noguchi C.T., and Schechter A.N. Hydroxyurea increases eNOS protein levels through inhibition of proteasome activity. Nitric Oxide 16 (2007) 371-378
198. Gladwin M.T., Shelhamer J.H., Ognibene F.P., Pease-Fye M.E., Nichols J.S., Link B., Patel D.B., Jankowski M.A., Pannell L.K., Schechter A.N., and Rodgers G.P. Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. Br. J. Haematol. 116 (2002) 436-444
199. Huang J., Kim-Shapiro D.B., and King S.B. Catalase-mediated nitric oxide formation from hydroxyurea. J. Med. Chem. 47 (2004) 3495-3501
200. King S.B. Nitric oxide production from hydroxyurea. Free Radic. Biol. Med. 37 (2004) 737-744
201. Pacelli R., Taira J., Cook J.A., Wink D.A., and Krishna M.C. Hydroxyurea reacts with heme proteins to generate nitric oxide. Lancet 347 (1996) 900
202. Kim-Shapiro D.B., King S.B., Bonifant C.L., Kolibash C.P., and Ballas S.K. Time resolved absorption study of the reaction of hydroxyurea with sickle cell hemoglobin. Biochim. Biophys. Acta 1380 (1998) 64-74
203. Kim-Shapiro D.B., King S.B., Shields H., Kolibash C.P., Gravatt W.L., and Ballas S.K. The reaction of deoxy-sickle cell hemoglobin with hydroxyurea. Biochim. Biophys. Acta 1428 (1999) 381-387
204. Rupon J.W., Domingo S.R., Smith S.V., Gummadi B.K., Shields H., Ballas S.K., King S.B., and Kim-Shapiro D.B. The reactions of myoglobin, normal adult hemoglobin, sickle cell hemoglobin and hemin with hydroxyurea. Biophys. Chem. 84 (2000) 1-11
205. Glover R.E., Ivy E.D., Orringer E.P., Maeda H., and Mason R.P. Detection of nitrosyl hemoglobin in venous blood in the treatment of sickle cell anemia with hydroxyurea. Mol. Pharmacol. 55 (1999) 1006-1010
206. Nahavandi M., Wyche M.Q., Perlin E., Tavakkoli F., and Castro O. Nitric oxide metabolites in sickle cell anemia patients after oral administration of hydroxyurea, hemoglobinopathy. Hematology 5 (2000) 335-339
207. Kato G.J., Onyekwere O.C., and Gladwin M.T. Pulmonary hypertension in sickle cell disease: relevance to children. Pediatr. Hematol. Oncol. 24 (2007) 159-170
208. Fitzhugh C.D., Wigfall D.R., and Ware R.E. Enalapril and hydroxyurea therapy for children with sickle nephropathy. Pediatr. Blood Cancer 45 (2005) 982-985
209. Hankins J.S., Helton K.J., McCarville M.B., Li C.S., Wang W.C., and Ware R.E. Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea. Pediatr. Blood Cancer (2007)
210. Kirkham F.J., and DeBaun M.R. Stroke in children with sickle cell disease. Curr. Treat. Options Neurol. 6 (2004) 357-375
211. Zinkham W.H., Seidler A.J., and Kickler T.S. Variable degrees of suppression of hemoglobin S synthesis in subjects with hemoglobin SS disease on a long-term transfusion regimen. J. Pediatr. 124 (1994) 215-219
212. Tancabelic J., Sheth S., Paik M., and Piomelli S. Serum transferrin receptor as a marker of erythropoiesis suppression in patients on chronic transfusion. Am. J. Hematol. 60 (1999) 121-125
213. Walters M.C., Storb R., Patience M., Leisenring W., Taylor T., Sanders J.E., Buchanan G.E., Rogers Z.R., Dinndorf P., Davies S.C., Roberts I.A., Dickerhoff R., Yeager A.M., Hsu L., Kurtzberg J., Ohene-Frempong K., Bunin N., Bernaudin F., Wong W.Y., Scott J.P., Margolis D., Vichinsky E., Wall D.A., Wayne A.S., Pegelow C., Redding-Lallinger R., Wiley J., Klemperer M., Mentzer W.C., Smith F.O., and Sullivan K.M. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood 95 (2000) 1918-1924
214. Krishnamurti L. Hematopoietic cell transplantation for sickle cell disease: state of the art. Expert Opin. Biol. Ther. 7 (2007) 161-172
215. Platt O.S., and Guinan E.C. Bone marrow transplantation in sickle cell anemia-the dilemma of choice. N. Engl. J. Med. 335 (1996) 426-428
216. Girgis R.E., Qureshi M.A., Abrams J., and Swerdlow P. Decreased exhaled nitric oxide in sickle cell disease: relationship with chronic lung involvement. Am. J. Hematol. 72 (2003) 177-184
217. Reiter C.D., and Gladwin M.T. An emerging role for nitric oxide in sickle cell disease vascular homeostasis and therapy. Curr. Opin. Hematol. 10 (2003) 99-107
218. Oppert M., Jorres A., Barckow D., Eckardt K.U., Frei U., and Kaisers U. Inhaled nitric oxide for ARDS due to sickle cell disease. Swiss Med. Wkly. 134 (2004) 165-167
219. Montero-Huerta P., Hess D.R., and Head C.A. Inhaled nitric oxide for treatment of sickle cell stroke. Anesthesiology 105 (2006) 619-621
220. Atz A.M., and Wessel D.L. Inhaled nitric oxide in sickle cell disease with acute chest syndrome. Anesthesiology 87 (1997) 988-990
221. Sullivan K.J., Goodwin S.R., Evangelist J., Moore R.D., and Mehta P. Nitric oxide successfully used to treat acute chest syndrome of sickle cell disease in a young adolescent. Crit. Care Med. 27 (1999) 2563-2568
222. Zuzak K.J., Gladwin M.T., Cannon III R.O., and Levin I.W. Imaging hemoglobin oxygen saturation in sickle cell disease patients using noninvasive visible reflectance hyperspectral techniques: effects of nitric oxide. Am. J. Physiol., Heart Circ. Physiol. 285 (2003) H1183-H1189
223. Weiner D.L., Hibberd P.L., Betit P., Cooper A.B., Botelho C.A., and Brugnara C. Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease. JAMA 289 (2003) 1136-1142
224. Bloomfield G.L., Holloway S., Ridings P.C., Fisher B.J., Blocher C.R., Sholley M., Bunch T., Sugerman H.J., and Fowler A.A. Pretreatment with inhaled nitric oxide inhibits neutrophil migration and oxidative activity resulting in attenuated sepsis-induced acute lung injury. Crit. Care Med. 25 (1997) 584-593
225. Dellinger R.P., Zimmerman J.L., Taylor R.W., Straube R.C., Hauser D.L., Criner G.J., Davis Jr. K., Hyers T.M., and Papadakos P. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Inhaled Nitric Oxide in ARDS Study Group. Crit. Care Med. 26 (1998) 15-23
226. Guidot D.M., Hybertson B.M., Kitlowski R.P., and Repine J.E. Inhaled NO prevents IL-1-induced neutrophil accumulation and associated acute edema in isolated rat lungs. Am. J. Physiol. 271 (1996) L225-L229
227. Fox-Robichaud A., Payne D., Hasan S.U., Ostrovsky L., Fairhead T., Reinhardt P., and Kubes P. Inhaled NO as a viable antiadhesive therapy for ischemia/reperfusion injury of distal microvascular beds. J. Clin. Invest. 101 (1998) 2497-2505
228. Cannon III R.O., Schechter A.N., Panza J.A., Ognibene F.P., Pease-Fye M.E., Waclawiw M.A., Shelhamer J.H., and Gladwin M.T. Effects of inhaled nitric oxide on regional blood flow are consistent with intravascular nitric oxide delivery. J. Clin. Invest. 108 (2001) 279-287
229. Schechter A.N., Gladwin M.T., and Cannon III R.O. NO solutions?. J. Clin. Invest. 109 (2002) 1149-1151
230. Garel M.C., Domenget C., Galacteros F., Martin-Caburi J., and Beuzard Y. Inhibition of erythrocyte sickling by thiol reagents. Mol. Pharmacol. 26 (1984) 559-565
231. Ferrali M., Signorini C., Ciccoli L., and Comporti M. Iron release and membrane damage in erythrocytes exposed to oxidizing agents, phenylhydrazine, divicine and isouramil. Biochem. J. 285 Pt 1 (1992) 295-301
232. Shalev O., Repka T., Goldfarb A., Grinberg L., Abrahamov A., Olivieri N.F., Rachmilewitz E.A., and Hebbel R.P. Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo. Blood 86 (1995) 2008-2013
233. Balla G., Vercellotti G.M., Eaton J.W., and Jacob H.S. Iron loading of endothelial cells augments oxidant damage. J. Lab. Clin. Med. 116 (1990) 546-554
234. Venters Jr. H.D., Bonilla L.E., Jensen T., Garner H.P., Bordayo E.Z., Najarian M.M., Ala T.A., Mason R.P., and Frey II W.H. Heme from Alzheimer's brain inhibits muscarinic receptor binding via thiyl radical generation. Brain Res. 764 (1997) 93-100
235. Duranski M.R., Greer J.J., Dejam A., Jaganmohan S., Hogg N., Langston W., Patel R.P., Yet S.F., Wang X., Kevil C.G., Gladwin M.T., and Lefer D.J. Cytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver. J. Clin. Invest. 115 (2005) 1232-1240
236. Bolli R. Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J. Mol. Cell. Cardiol. 33 (2001) 1897-1918
237. Bell R.M., Maddock H.L., and Yellon D.M. The cardioprotective and mitochondrial depolarising properties of exogenous nitric oxide in mouse heart. Cardiovasc. Res. 57 (2003) 405-415
238. Jones S.P., and Bolli R. The ubiquitous role of nitric oxide in cardioprotection. J. Mol. Cell. Cardiol. 40 (2006) 16-23
239. Gianetti J., Del Sarto P., Bevilacqua S., Vassalle C., De Filippis R., Kacila M., Farneti P.A., Clerico A., Glauber M., and Biagini A. Supplemental nitric oxide and its effect on myocardial injury and function in patients undergoing cardiac surgery with extracorporeal circulation. J. Thorac. Cardiovasc. Surg. 127 (2004) 44-50
240. Dezfulian C., Raat N., Shiva S., and Gladwin M.T. Role of the anion nitrite in ischemia-reperfusion cytoprotection and therapeutics. Cardiovasc. Res. 75 (2007) 327-338
241. Lu P., Liu F., Yao Z., Wang C.Y., Chen D.D., Tian Y., Zhang J.H., and Wu Y.H. Nitrite-derived nitric oxide by xanthine oxidoreductase protects the liver against ischemia-reperfusion injury. Hepatobiliary Pancreat. Dis. Int. 4 (2005) 350-355
242. Webb A., Bond R., McLean P., Uppal R., Benjamin N., and Ahluwalia A. Reduction of nitrite to nitric oxide during ischemia protects against myocardial ischemia-reperfusion damage. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 13683-13688
243. Gladwin M.T., Schechter A.N., Kim-Shapiro D.B., Patel R.P., Hogg N., Shiva S., Cannon III R.O., Kelm M., Wink D.A., Espey M.G., Oldfield E.H., Pluta R.M., Freeman B.A., Lancaster Jr. J.R., Feelisch M., and Lundberg J.O. The emerging biology of the nitrite anion. Nat. Chem. Biol. 1 (2005) 308-314
244. Jung K.H., Chu K., Ko S.Y., Lee S.T., Sinn D.I., Park D.K., Kim J.M., Song E.C., Kim M., and Roh J.K. Early intravenous infusion of sodium nitrite protects brain against in vivo ischemia-reperfusion injury. Stroke 37 (2006) 2744-2750
245. Tripatara P., Patel N.S., Webb A., Rathod K., Lecomte F.M., Mazzon E., Cuzzocrea S., Yaqoob M.M., Ahluwalia A., and Thiemermann C. Nitrite-derived nitric oxide protects the rat kidney against ischemia/reperfusion injury in vivo: role for xanthine oxidoreductase. J. Am. Soc. Nephrol. 18 (2007) 570-580
246. Cosby K., Partovi K.S., Crawford J.H., Patel R.P., Reiter C.D., Martyr S., Yang B.K., Waclawiw M.A., Zalos G., Xu X., Huang K.T., Shields H., Kim-Shapiro D.B., Schechter A.N., Cannon III R.O., and Gladwin M.T. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat. Med. 9 (2003) 1498-1505
247. Morris C.R., Vichinsky E.P., van Warmerdam J., Machado L., Kepka-Lenhart D., Morris Jr. S.M., and Kuypers F.A. Hydroxyurea and arginine therapy: impact on nitric oxide production in sickle cell disease. J. Pediatr. Hematol. Oncol. 25 (2003) 629-634
248. Boucher J.L., Custot J., Vadon S., Delaforge M., Lepoivre M., Tenu J.P., Yapo A., and Mansuy D. N omega-hydroxyl-L-arginine, an intermediate in the L-arginine to nitric oxide pathway, is a strong inhibitor of liver and macrophage arginase. Biochem. Biophys. Res. Commun. 203 (1994) 1614-1621
249. Buga G.M., Singh R., Pervin S., Rogers N.E., Schmitz D.A., Jenkinson C.P., Cederbaum S.D., and Ignarro L.J. Arginase activity in endothelial cells: inhibition by NG-hydroxy-L-arginine during high-output NO production. Am. J. Physiol. 271 (1996) H1988-H1998
250. Moali C., Boucher J.L., Sari M.A., Stuehr D.J., and Mansuy D. Substrate specificity of NO synthases: detailed comparison of L-arginine, homo-L-arginine, their N omega-hydroxy derivatives, and N omega-hydroxynor-L-arginine. Biochemistry 37 (1998) 10453-10460
251. Schmidt T.S., and Alp N.J. Mechanisms for the role of tetrahydrobiopterin in endothelial function and vascular disease. Clin. Sci. (Lond.) 113 (2007) 47-63
252. Hasegawa H., Sawabe K., Nakanishi N., and Wakasugi O.K. Delivery of exogenous tetrahydrobiopterin (BH4) to cells of target organs: role of salvage pathway and uptake of its precursor in effective elevation of tissue BH4. Mol. Genet. Metab. 86 Suppl 1 (2005) S2-S10
253. Reed J.D., Redding-Lallinger R., and Orringer E.P. Nutrition and sickle cell disease. Am. J. Hematol. 24 (1987) 441-455
254. Steinberg M.H. Clinical trials in sickle cell disease: adopting the combination chemotherapy paradigm. Am. J. Hematol. (2007)
255. Ohnishi S.T., Ohnishi T., and Ogunmola G.B. Sickle cell anemia: a potential nutritional approach for a molecular disease. Nutrition 16 (2000) 330-338
256. MacDermott R.P. Progress in understanding the mechanisms of action of 5-aminosalicylic acid. Am. J. Gastroenterol. 95 (2000) 3343-3345
257. Yuditskaya S., Hoehn G., Suffredini A.F., Xu X., Munson P., Gladwin M.T., and Kato G.J. Proteomic identification of dysregulated apolipoprotein expression in pulmonary hypertension secondary to sickle cell disease [abstract]. Society for Free Radical Biology and Medicine Meeting (2005) Austin, TX
258. Sultana C., Shen Y., Rattan V., Johnson C., and Kalra V.K. Interaction of sickle erythrocytes with endothelial cells in the presence of endothelial cell conditioned medium induces oxidant stress leading to transendothelial migration of monocytes. Blood 92 (1998) 3924-3935
259. Mahaseth H., Vercellotti G.M., Welch T.E., Bowlin P.R., Sonbol K.M., Hsia C.J., Li M., Bischof J.C., Hebbel R.P., and Belcher J.D. Polynitroxyl albumin inhibits inflammation and vasoocclusion in transgenic sickle mice. J. Lab. Clin. Med. 145 (2005) 204-211
260. Ferdinandy P., and Schulz R. Peroxynitrite: toxic or protective in the heart?. Circ. Res. 88 (2001) E12-E13
261. Yasmin W., Strynadka K.D., and Schulz R. Generation of peroxynitrite contributes to ischemia-reperfusion injury in isolated rat hearts. Cardiovasc. Res. 33 (1997) 422-432
262. Steen R.G., Helton K.J., Horwitz E.M., Benaim E., Thompson S., Bowman L.C., Krance R., Wang W.C., and Cunningham J.M. Improved cerebrovascular patency following therapy in patients with sickle cell disease: initial results in 4 patients who received HLA-identical hematopoietic stem cell allografts. Ann. Neurol. 49 (2001) 222-229
263. Bialecki E.S., and Bridges K.R. Sildenafil relieves priapism in patients with sickle cell disease. Am. J. Med. 113 (2002) 252
264. Derchi G., Forni G.L., Formisano F., Cappellini M.D., Galanello R., D'Ascola G., Bina P., Magnano C., and Lamagna M. Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica 90 (2005) 452-458
265. Machado R.F., Martyr S., Kato G.J., Barst R.J., Anthi A., Robinson M.R., Hunter L., Coles W., Nichols J., Hunter C., Sachdev V., Castro O., and Gladwin M.T. Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br. J. Haematol. 130 (2005) 445-453
266. Burnett A.L., Bivalacqua T.J., Champion H.C., and Musicki B. Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism. Urology 67 (2006) 1043-1048
267. Ferrario C.; ABdelhamed A. I.; Moore M. AII antagonists in hypertension, heart failure, and diabetic nephropathy: focus on losartan. Curr. Med. Res. Opin. 20 (2004) 279-293
268. Walters M.C., Patience M., Leisenring W., Rogers Z.R., Aquino V.M., Buchanan G.R., Roberts I.A., Yeager A.M., Hsu L., Adamkiewicz T., Kurtzberg J., Vichinsky E., Storer B., Storb R., and Sullivan K.M. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol. Blood Marrow Transplant. 7 (2001) 665-673
269. Kean L.S., Manci E.A., Perry J., Balkan C., Coley S., Holtzclaw D., Adams A.B., Larsen C.P., Hsu L.L., and Archer D.R. Chimerism and cure: hematologic and pathologic correction of murine sickle cell disease. Blood 102 (2003) 4582-4593
270. Haque A.K., Gokhale S., Rampy B.A., Adegboyega P., Duarte A., and Saldana M.J. Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases. Hum. Pathol. 33 (2002) 1037-1043
271. Aessopos A., Farmakis D., and Loukopoulos D. Elastic tissue abnormalities resembling pseudoxanthoma elasticum in beta thalassemia and the sickling syndromes. Blood 99 (2002) 30-35
272. Koshy M., Thomas C., and Goodwin J. Vascular lesions in the central nervous system in sickle cell disease (neuropathology). J. Assoc. Acad. Minor Phys. 1 (1990) 71-78
273. Oyesiku N.M., Barrow D.L., Eckman J.R., Tindall S.C., and Colohan A.R. Intracranial aneurysms in sickle-cell anemia: clinical features and pathogenesis. J. Neurosurg. 75 (1991) 356-363
274. Tsomi K., Karagiorga-Lagana M., Karabatsos F., Fragodimitri C., van Vliet-Konstantinidou C., Premetis E., and Stamoulakatou A. Arterial elastorrhexis in beta-thalassaemia intermedia, sickle cell thalassaemia and hereditary spherocytosis. Eur. J. Haematol. 67 (2001) 135-141
275. Osarogiagbon U.R., Choong S., Belcher J.D., Vercellotti G.M., Paller M.S., and Hebbel R.P. Reperfusion injury pathophysiology in sickle transgenic mice. Blood 96 (2000) 314-320
276. Solovey A., Kollander R., Shet A., Milbauer L.C., Choong S., Panoskaltsis-Mortari A., Blazar B.R., Kelm R.J., and Hebbel R.P. Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood (2004)
277. Downes S.M., Hambleton I.R., Chuang E.L., Lois N., Serjeant G.R., and Bird A.C. Incidence and natural history of proliferative sickle cell retinopathy: observations from a cohort study. Ophthalmology 112 (2005) 1869-1875
278. Preul M.C., Cendes F., Just N., and Mohr G. Intracranial aneurysms and sickle cell anemia: multiplicity and propensity for the vertebrobasilar territory. Neurosurgery 42 (1998) 971-977 discussion 977-978
279. Firth P.G., and Peterfreund R.A. Management of multiple intracranial aneurysms: neuroanesthetic considerations of sickle cell disease. J. Neurosurg. Anesthesiol. 12 (2000) 366-371
280. Kirkham F.J. Therapy insight: stroke risk and its management in patients with sickle cell disease. Nat. Clin. Pract. Neurol. 3 (2007) 264-278
281. Steen R.G., Xiong X., Langston J.W., and Helton K.J. Brain injury in children with sickle cell disease: prevalence and etiology. Ann. Neurol. 54 (2003) 564-572
282. Solovey A.A., Solovey A.N., Harkness J., and Hebbel R.P. Modulation of endothelial cell activation in sickle cell disease: a pilot study. Blood 97 (2001) 1937-1941
283. Cheung A.T., Chen P.C., Larkin E.C., Duong P.L., Ramanujam S., Tablin F., and Wun T. Microvascular abnormalities in sickle cell disease: a computer-assisted intravital microscopy study. Blood 99 (2002) 3999-4005
284. Solovey A., Lin Y., Browne P., Choong S., Wayner E., and Hebbel R.P. Circulating activated endothelial cells in sickle cell anemia. N. Engl. J. Med. 337 (1997) 1584-1590
285. Wigfall D.R., Ware R.E., Burchinal M.R., Kinney T.R., and Foreman J.W. Prevalence and clinical correlates of glomerulopathy in children with sickle cell disease. J. Pediatr. 136 (2000) 749-753
286. Bhathena D.B., and Sondheimer J.H. The glomerulopathy of homozygous sickle hemoglobin (SS) disease: morphology and pathogenesis. J. Am. Soc. Nephrol. 1 (1991) 1241-1252
287. Vogler C., Wood E., Lane P., Ellis E., Cole B., and Thorpe C. Microangiopathic glomerulopathy in children with sickle cell anemia. Pediatr. Pathol. Lab. Med. 16 (1996) 275-284
288. McLeod D.S., Merges C., Fukushima A., Goldberg M.F., and Lutty G.A. Histopathologic features of neovascularization in sickle cell retinopathy. Am. J. Ophthalmol. 124 (1997) 455-472
289. Okpala I. The intriguing contribution of white blood cells to sickle cell disease-a red cell disorder. Blood Rev. 18 (2004) 65-73